Plenary Session: US Pharmaceutical Policy: Leading or Following?
Moderator
Dana P. Goldman, PhD, University of Southern California Schaeffer Institute for Public Policy & Government Service, Los Angeles, CA, United States
Speakers
Courtney Piron, Novartis, Washington, DC, United States; Liz Fowler, PhD, JD, Johns Hopkins Bloomberg School of Public Health, Arlington, VA, United States; Inmaculada Hernandez, PhD, CMS, Washington, DC, United States
Americans have run out of patience with paying three times more for innovative medicine than other developed countries. President Trump is negotiating ways to bring US drug prices in line with other countries through a most-favored-nation (MFN) approach. This strategy builds on efforts of the Biden Administration's Inflation Reduction Act (IRA) to directly negotiate drug prices in Medicare. In a wide-ranging discussion with Trump Administration officials, the biopharmaceutical industry, and payers, we will discuss MFN, IRA, and other efforts to lower drug prices in the United States -- with a view toward the economic and regulatory consequences and long-term consequences for the US and abroad.
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment